AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02505165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: • The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
Study NCT02505165 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ESO
Description: This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
Study NCT02989610 — intervention group
Intervention type: DEVICE
Intervention: Omnidirectional stimulation
Description: At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
Study NCT02989610 — intervention group
Intervention type: DEVICE
Intervention: Directional stimulation
Description: At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
Study NCT04179474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
Study NCT04179474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
Study NCT04179474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: 2 SC injections of galcanezumab 120 mg \[Intervention C\].
Study NCT03934437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLTCR
Description: mHealth-enhanced Linkage to Care and Retention
Study NCT03934437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTCR
Description: Linkage and Retention Services (Standard-of-Care)
Study NCT01083901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: high intensity progressive resistance exercise training
Study NCT01083901 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: high intensity progressive resistance exercise training
Study NCT04554927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEB-Application
Description: The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
Study NCT04554927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard accompaniment
Description: Personalized schedule of medical follow-up given to the patient
Study NCT03945760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib 2 mg
Study NCT03945760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04339361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
Study NCT04339361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal dinoprostone
Description: vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study NCT04339361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study NCT00377715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Study NCT00377715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02224300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based education of venous leg ulcer nursing care
Description: Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
Study NCT02702271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX
Description: Left atrial appendage closure with WATCHMAN FLX
Study NCT02933827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIXCYTE
Description: Adipose-derived stem cells (ADSCs)
Study NCT00858559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator with Home Monitoring function
Description: Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
Study NCT00858559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implantable cardioverter defibrillator
Description: Implantable cardioverter defibrillators used as standard devices without Home Monitoring
Study NCT02632383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Young with Diabetes - app
Description: The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder
Study NCT01506817 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic contrast-enhanced MRI of the hands
Description: The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
Study NCT00540007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT00854607 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
Study NCT03706274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-188
Description: CX-188
Study NCT03205007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion nutrition program
Description: Health promotion nutrition program
Study NCT03903952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin B12 and folate
Description: Vitamin B12 and folate levels in blood
Study NCT02399059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic lavage
Description: Peritoneal irrigation with gentamycin-clindamycin solution
Study NCT02399059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline lavage
Description: Peritoneal irrigation with normal saline
Study NCT01254994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
Study NCT01254994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional comprehensive medical treatment
Description: bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
Study NCT01042002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: High intensity exercise 3xweek for minimum 6 weeks
Study NCT04253756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20-gauge BD Nexiva Diffusics
Description: The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
Study NCT00091507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK
Description: Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
Study NCT00091507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
Study NCT03888573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching protocol
Description: Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
Study NCT03807362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
Study NCT00741234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: SB939 taken orally in a 4-week cycle.
Study NCT00741234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine taken orally with SB939 in a 4-week cycle
Study NCT01579123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty
Description: With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
Study NCT01579123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser atherectomy
Description: Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
Study NCT02009176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Anatomical Hepatectomy
Description: We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
Study NCT04118855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
Study NCT04118855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg by mouth twice each day for 12 weeks prior to nephrectomy
Study NCT02177864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Study NCT02177864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (low fiber bar)
Study NCT03996980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses Versus a flat insole
Description: Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
Study NCT03996980 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Custom-made foot orthoses Versus a flat insole
Description: Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
Study NCT01812291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1: Diabetes-Specific CBT (5 group sessions)
Description: Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement
Study NCT01812291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2: Depression-Specific CBT (6 single sessions)
Description: Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity.
Study NCT01812291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 3: Referral to Psychotherapist and/or Psychiatrist
Description: Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
Study NCT01812291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Education
Description: Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes
Study NCT04399850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis group
Description: Patients who receive hypnosis
Study NCT01376180 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine
Description: Administered according to the prescribing information in the locally approved label by the authorities
Study NCT00995540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INGAP Peptide
Description: 100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
Study NCT00995540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INGAP Peptide
Description: 200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
Study NCT00995540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid subcutaneous injection for 12 weeks
Study NCT03430089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.25 mL, 2 doses
Description: Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
Study NCT03430089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, 2 doses
Description: Administered intramuscularly into the deltoid muscle, 28 days apart
Study NCT03430089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shz QIV 0.5 mL, single dose
Description: Administered intramuscularly into the deltoid muscle.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Ketorolac 30 mg IV
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low and epinephrine (T1)
Description: A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine low combined with epinephrine (C1)
Description: A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study NCT02162134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Zantac 50mg IV
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study NCT00818350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNITINIB
Description: 50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
Study NCT02391688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam
Study NCT02391688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Study NCT02391688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Study NCT00644215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and Mitomycin
Description: * 5-FU injection 5mg~* Mitomycin drop 0.02%
Study NCT02009176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Aon-anatomical Hepatectomy
Description: We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
Study NCT00583557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: IV 10mg/kg Q28 days
Study NCT04145128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: AG-881 tablets.
Study NCT03048708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: patients who had received treatment with bariatric surgery for medical reasons
Study NCT01131312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thinprep
Description: Pap test
Study NCT01131312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid capture 2
Description: Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
Study NCT01131312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
Study NCT02657278 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arterial Revascularization surgery or Endovascular procedure
Description: Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
Study NCT03539562 — intervention group
Intervention type: DRUG
Intervention: Morphine Sulfate and Promethazine
Description: Morphine sulfate and promethazine
Study NCT00813930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTERxVENT lifestyle modification program
Description: It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
Study NCT02401672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine high combined with epinephrine (C2)
Description: A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low (T2)
Description: A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
Study NCT03399435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine low (C3)
Description: A single injection: Bupivacaine from 10 to 80 mg.
Study NCT03399435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine high (C4)
Description: A single injection: Bupivacaine 100 mg.
Study NCT03399435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin (T3)
Description: A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with epinephrine (T4)
Description: A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.